SARS-CoV-2 is the etiological pathogen of the COVID-19 pandemic, which led to more than 6.5 million deaths since the beginning of the outbreak in December 2019. The unprecedented disruption of social life and public health caused by COVID-19 calls for fast-track development of diagnostic kits, vaccines, and antiviral drugs. Small molecule antivirals are essential complements of vaccines and can be used for the treatment of SARS-CoV-2 infections. Currently, there are three FDA-approved antiviral drugs, remdesivir, molnupiravir, and paxlovid. Given the moderate clinical efficacy of remdesivir and molnupiravir, the drug–drug interaction of paxlovid, and the emergence of SARS-CoV-2 variants with potential drug-resistant mutations, there is a pressing need for additional antivirals to combat current and future coronavirus outbreaks.

中文翻译：

---

SARS-CoV-2 主要蛋白酶药物设计、检测方法开发和耐药性研究

SARS-CoV-2 是 COVID-19 大流行的病原体，自 2019 年 12 月爆发以来已导致超过 650 万人死亡。COVID-19 对社会生活和公共卫生造成前所未有的破坏，呼吁快速开发诊断试剂盒、疫苗和抗病毒药物。小分子抗病毒药物是疫苗的重要补充，可用于治疗 SARS-CoV-2 感染。目前，FDA批准的抗病毒药物有瑞德西韦、莫努匹拉韦和帕克洛维德三种。鉴于瑞德西韦和莫努匹拉韦的中等临床疗效、帕克洛维德的药物相互作用，以及具有潜在耐药突变的 SARS-CoV-2 变体的出现，迫切需要更多的抗病毒药物来应对当前和未来的冠状病毒爆发。